First patient dosed with Nuformix cocrystal product
Cambridge, UK, 22 March 2019: Nuformix (LSE: NFX), the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces it has commenced clinical studies for the Company’s lead asset NXP001.
NXP001 is in development as a treatment for chemotherapy-induced nausea and vomiting (“CINV”), a large, under-exploited and growing market, which in demographic terms comprises one third of global cancer patients.
First dosing of NXP001 took place successfully on 20 March 2019 in a cross-over study that aims to measure the relative bioavailability of NXP001 compared to Merck’s EMEND® in healthy subjects. Dosing will complete during April 2019 with results expected by end H1 2019